肺癌化疗严重药品不良反应的危险因素分析  

Analysis of risk factors of serious adverse drug reactions in chemotherapy of lung cancer patients

作　　者：王晓辉[1] 吴斌[2] 刘瑾[1] 朱珺[1] 

机构地区：[1]上海交通大学医学院附属胸科医院药剂科,上海200030 [2]上海交通大学医学院附属仁济医院药剂科,上海200001

出　　处：《药学服务与研究》2012年第4期303-306,共4页Pharmaceutical Care and Research

基　　金：上海市市级医院临床管理优化项目(No.SHDC2011612)

摘　　要：目的:调查肺癌病人住院化疗期间发生严重药品不良反应(adverse drug reactions,ADRs)的危险因素。方法:采用多因素Logistic回归分析236例肺癌病人的临床因素与化疗期间发生严重ADRs的关系。结果:年龄,性别,肝、肾功能,以及同时患有多种疾病且服用多种药物均能影响肺癌病人化疗期间严重ADRs的发生。老年病人和女性病人发生严重ADRs的风险比分别为1.048和1.033。与严重ADRs相关的临床因素按风险比由大到小依次为:肝功能损害>肾功能损害>同时患有多种疾病且服用多种药物。结论:对于存在上述风险因素的病人应监测血药浓度,注意化疗方案的选择以及联合用药情况,以减少严重ADRs的发生。Objective： To investigate risk factors of serious adverse drug reactions（ADRs） in chemotherapy of inpatients with lung cancer. Methods： The relationship between clinical factors and serious ADRs of chemotherapy in 236 lung cancer pa tients was analyzed by the Logistic regression model. Results： Age, gender, liver function, renal function, comorbidities and mixed administration of more than one kind of drugs could all affect the incidence of serious ADRs. The odds ratios（OR） of se rious ADRs in the aged and female patients were 1. 048 and 1. 033 ,respectively. Clinical factors associated with serious ADRs in the descending order of severeness were liver dysfunction, renal dysfunction, eomorbidities and mixed administration of more than one kind of drugs. Conclusion： In order to reduce the incidence of serious ADRs in patients with these risk factors, more at tention should be paid to the blood concentration monitoring of chemotherapeutic drugs,the selection of chemotherapy regimens and the combined use of drugs.

关 键 词：肺肿瘤 抗肿瘤联合化疗方案 药物副反应报告系统 危险因素 

分 类 号：R979.1[医药卫生—药品]